Given that glycolysis is a key driver of FLS proliferation and joint inflammation, targeting the m6A modification of GLUT1 could offer a novel approach to disrupt the metabolic and inflammatory processes in RA synovium. The gene discussed is SLC2A1; the disease is rheumatoid arthritis.